IgAN
Advertisement
A study examined whether COVID-19 independently affects the subsequent trajectory of kidney function in patients with IgAN.
A study analyzed the fecal microbiome of patients with IgA nephropathy, focusing on their immune response to microbiota.
Researchers examined the role of urinary sodium excretion and the progression of immunoglobulin A nephropathy (IgAN).
Could adding serum C3 and C4 levels to existing predictive models for IgA nephropathy (IgAN) improve their accuracy?
Jonathan Barratt discussed advances in IgA nephropathy treatment with Joel Topf at ASN Kidney Week 2024.
A novel endothelin receptor type A selective antagonist showed a meaningful reduction in proteinuria in patients with IgAN.
Treatment of IgA nephropathy with felzartamab led to sustained proteinuria reduction and reduced eGFR decline.
Jonathan Barratt discussed his research on the anti-APRIL antibody sibeprenlimab in the treatment of IgA nephropathy.
BAFF and APRIL inhibitor atacicept reduced UPCR, hematuria, and Gd-IgA1 and stabilized eGFR in patients with IgAN.
IgAN was a hot topic at ASN Kidney Week and was the focus of an exhibitor spotlight on pathogenesis and the role of APRIL.
Could the systemic inflammatory response index (SIRI) be a useful measure of renal prognosis in IgA nephropathy (IgAN)?
Diffuse magnetic imaging resonance shows promise for evaluating clinical and pathological changes in patients with IgAN.
Surveyed physicians indicated that IgAN patients were referred to them late and not all potential cases had a timely biopsy.
C3 plays a key role in the formation of Gd-IgA1-containing IC with a nephritogenic capacity for IgAN.
Clinical improvement does not always reflect pathology, so renal biopsy may be needed to determine IgAN treatment efficacy.
Even when levels are below the current KDIGO threshold, proteinuria in IgAN indicates a risk of kidney failure.
Researchers found evidence that anti-mesangium IgA is involved in the pathogenesis of human IgAN.
Data from patient charts and surveys of nephrologists shed light on the future of individualizing treatment for IgAN.
A biopsy registry linked with administrative databases proved to be a practical way of studying IgAN at the population level.
Researchers identified six candidate loci that were significantly associated with IgA nephropathy prognosis.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.